Skip to main content
Vineeta Agarwala on Muck Rack

Vineeta Agarwala

Palo Alto
As seen in: Raising Health, The a16z Show, Apple Podcasts, Nature, PLOS, a16z
gp @a16z bio | physician, adjunct clinical prof @stanfordmed | prev @gvteam, product @flatironhealth, mdphd @broadinstitute | out-tweeting @paraga @littleansh
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vineeta

Contact Vineeta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Science and Supply of GLP-1s with Brooke Boyarsky Pratt

|
By Vineeta Agarwala, Kris Tatiossian, Olivia Webb, Carolyn Jasik
| a16z
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health. Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time. This is the second episode in our series on the science and supply of GLP-1s.
Open in Who Shared Issue with article?

Investing in Valar Labs

|
By Vineeta Agarwala, Jonathan Lai Verified, Jack Soslow, Luke Timmerman Verified
| a16z
“I remember reading an article…where they measured the efficiency of locomotion for all the species on planet Earth. And the condor won. Humans came in about a third of the way down the list, which was not such a great showing for the crown of creation. But somebody had the imagination to test the efficiency of a human riding a bicycle. Human on the bicycle blew away the condor, all the way off the top of the list.
Open in Who Shared Issue with article?

Virtual Data Rooms: The Unsung Hero of Biotech Financing

|
By Bryan Faust, Becky Pferdehirt, Vineeta Agarwala, Zak Doric
| a16z
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. This simplicity is of course shrouded in the complexity of biology, and demands that biotech companies thoughtfully de-risk existential concerns throughout the drug development lifecycle.
Open in Who Shared Issue with article?
See all 59 articles